Suboxone: The Light At The End Of The Tunnel

Gain knowledge and share experiences with Suboxone, to obtain support through coming together with one bond in common-To help, support and educate others.
 
HomeHome  PortalPortal  SearchSearch  RegisterRegister  Log in  

Share | 
 

  FDA Safety Alert: Reports of Accidental Overdose from Medication Dosing Errors

Go down 
AuthorMessage
nannamom
Admin
avatar

Female
Number of posts : 2207
Age : 60
Humor : Once you choose hope, anything’s possible. -Christopher Reeve
Registration date : 2008-11-09

PostSubject: FDA Safety Alert: Reports of Accidental Overdose from Medication Dosing Errors   Tue 11 Jan 2011, 8:32 pm






Morphine Sulfate Oral Solution 100 mg per 5 mL (20 mg/mL): Medication Use Error - Reports of Accidental Overdose



ISSUE: Roxane Laboratories and FDA notified healthcare professionals of serious adverse events and deaths resulting from accidental overdose of morphine sulfate oral solutions, especially when using the high potency 100 mg/5mL product. In most of these cases, morphine sulfate oral solutions ordered in milligrams (mg) were mistakenly interchanged for milliliters (mL) of the product. The approval of this product is part of FDA’s unapproved drugs initiative. Prior to the recent approval, Roxane marketed a morphine sulfate oral solution with the strength expressed as 20 mg/mL, using a container label and carton labeling that had brown lettering on a white background. The newly approved product labeling and packaging feature revisions intended to reduce the risk of medication errors.

BACKGROUND: Morphine Sulfate Oral Solution 100 mg per 5 mL (20 mg/mL) is indicated for relief of moderate to severe acute and chronic pain in opioid-tolerant patients.

RECOMMENDATION: See Roxane's "Dear Healthcare Professional Letter" for a complete description and photos of labeling and product packaging changes. Changes include:

  • A warning stating “ONLY FOR USE IN PATIENTS WHO ARE OPIOID TOLERANT” is displayed in a box to highlight that the morphine sulfate oral solution 100 mg per 5 mL (20 mg/mL) is indicated for use in opioid-tolerant patients only. The 100 mg per 5 mL concentration of morphine sulfate may cause fatal respiratory depression when administered to patients not previously exposed to opioids.

  • The strength is presented as 100 mg per 5 mL followed by a less prominently displayed concentration of (20 mg/mL). The intent of this designation is to help differentiate this product from the 20 mg/5 mL morphine sulfate product.

  • A bright yellow background is used on multiple sides of this product to differentiate the morphine sulfate oral solution 100 mg per 5 mL (20 mg/mL) from other morphine sulfate oral solutions marketed by Roxane with a white background.

  • The drug name, strength and concentration are displayed in white lettering on a red background as an additional means of differentiating this product from other concentrations of morphine sulfate oral solutions.

  • A reminder is presented to the pharmacist to dispense the product to each patient with the enclosed Medication Guide.

  • Both the 30 mL and 120 mL bottles of morphine sulfate 100 mg per 5 mL (20 mg/mL) oral solution are packaged with a calibrated oral syringe to provide accurate dose measurements. Healthcare providers should read the instructions in the Medication Guide that describe the correct use of the oral syringe in order to help prevent medication errors from occurring.

  • Healthcare providers should discuss the correct use of the oral syringe with their patients.



(The "Dear Healthcare Professional Letter" can be viewed at the following link:Roxane laboratories)
http://www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/UCM239561.pdf

(Medication Guide, Morphine Sulfate, Roxane Laboratories:)
http://www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/UCM239632.pdf

(Prescribing Information, Morphine Sulfate Oral Solution: Roxane Laboratories)
http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022195s002lbl.pdf

Source: FDA
http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm239559.htm





Another update from the FDA


Acetaminophen Prescription Products Limited to 325 mg Per Dosage Unit: Drug Safety Communication

ISSUE: FDA notified healthcare professionals that it has asked drug manufacturers to limit the strength of acetaminophen in prescription drug products, predominantly combinations of acetaminophen and opioids, to 325 mg per tablet, capsule, or other dosage unit, making these products safer for patients. This action will help to reduce the risk of severe liver injury and allergic reactions associated with acetaminophen. A Boxed Warning highlighting the potential for severe liver injury and a Warning highlighting the potential for allergic reactions (swelling of the face, mouth, and throat, difficulty breathing, itching, or rash) will be added to the label of all prescription drug products that contain acetaminophen.

BACKGROUND: Acetaminophen, one of the most commonly used drugs in the United States, is widely and effectively used in both prescription and over-the-counter (OTC) products to reduce pain and fever. Examples of prescription products that contain acetaminophen include hydrocodone with acetaminophen (Vicodin, Lortab), and oxycodone with acetaminophen (Tylox, Percocet). OTC products containing acetaminophen (e.g., Tylenol) are not affected by this action. Information about the potential for liver injury is already required on the label for OTC products containing acetaminophen. FDA is continuing to evaluate ways to reduce the risk of acetaminophen related liver injury from OTC products. No drug shortages are expected, because the 3-year implementation period should permit adequate time for necessary reformulations.

RECOMMENDATION: Healthcare professionals were reminded to advise patients not to exceed the acetaminophen maximum total daily dose (4 grams/day), and not to drink alcohol while taking acetaminophen-containing medications.

Healthcare professionals were encouraged to inform patients that there is no immediate danger to patients who take these combination pain medications, and patients should continue to take them as directed by their health care provider. The Drug Safety Communication provides additional information for healthcare professionals, information for patients, a data summary and a list of all affected products.

_________________
Nannamom
db622@hotmail.com


"I will let yesterday end so that today can begin."


Last edited by nannamom on Fri 14 Jan 2011, 3:40 pm; edited 1 time in total (Reason for editing : add content/update)
Back to top Go down
http://www.suboxoneassistedtreatment.org
 
FDA Safety Alert: Reports of Accidental Overdose from Medication Dosing Errors
Back to top 
Page 1 of 1
 Similar topics
-
» Overheat safety trip light - rapid flashing constantly
» Jeudi 18 avril - E-mails, l'overdose
» EMPTY YOUR SAFETY DEPOSIT BOXES NOW!!!! RAID!!!
» DO NOT FLY... DANGEROUS RADIATION !!!!!!!!! ALERT !!!!!!!!!!!
» Siberia, the Game. Spoiler Alert

Permissions in this forum:You cannot reply to topics in this forum
Suboxone: The Light At The End Of The Tunnel :: Announcements :: Moderator Announcements-
Jump to: